Want to see SRTS full AI Analyst Report?
SRTS Stock Chart & Stats
$3.52
-$0.31(-4.45%)
At close: 4:00 PM EST
$3.52
-$0.31(-4.45%)
Day’s Range― - ―
52-Week Range$2.66 - $5.92
Previous CloseN/A
Volume208.66K
Average Volume (3M)82.22K
Market Cap
$50.54M
Enterprise Value$27.02M
Total Cash (Recent Filing)$18.33M
Total Debt (Recent Filing)$407.00K
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Jul 30, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding16,462,059
10 Day Avg. Volume39,755
30 Day Avg. Volume82,217
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.35
Price to Sales (P/S)2.36
P/FCF Ratio195.73
Enterprise Value/Market Cap0.53
Enterprise Value/Revenue1.20
Enterprise Value/Gross Profit3.18
Enterprise Value/Ebitda-3.37
Forecast
1Y Price Target
$5.67Price Target Upside60.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.35
Revenue Forecast (FY)$25.14M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceSensus Healthcare reported 3Q25 results with revenue, gross margin, and GAAP EPS all above consensus estimates.
Reimbursement PoliciesMedicare proposed a physician fee schedule that would significantly increase reimbursement for the delivery of a code of SRT.
Technology AdoptionThe newly published CPT codes for SRT treatment of nonmelanoma skin cancer enhance physician economics and broaden adoption of the technology.
Bears Say
Reimbursement LimitationsA proposed Local Coverage Determination to limit the reimbursement for ultrasound has a negative impact on topline sales since May 2025.
Revenue DeclineTotal revenue was $7.3M, representing 21% YoY decline and missing our projection of $8.3M.
Sales ExpectationsRevenue and gross margin estimates for 2025 and 2026 have been lowered due to expectations of lower SRT system sales.
Sensus Healthcare News
SRTS FAQ
What was Sensus Healthcare, Inc.’s price range in the past 12 months?
Sensus Healthcare, Inc. lowest stock price was $2.66 and its highest was $5.92 in the past 12 months.
What is Sensus Healthcare, Inc.’s market cap?
Sensus Healthcare, Inc.’s market cap is $50.54M.
When is Sensus Healthcare, Inc.’s upcoming earnings report date?
Sensus Healthcare, Inc.’s upcoming earnings report date is Jul 30, 2026 which is in 24 days.
How were Sensus Healthcare, Inc.’s earnings last quarter?
Sensus Healthcare, Inc. released its earnings results on May 07, 2026. The company reported -$0.16 earnings per share for the quarter, missing the consensus estimate of -$0.125 by -$0.035.
Is Sensus Healthcare, Inc. overvalued?
According to Wall Street analysts Sensus Healthcare, Inc.’s price is currently Undervalued.
Does Sensus Healthcare, Inc. pay dividends?
Sensus Healthcare, Inc. does not currently pay dividends.
What is Sensus Healthcare, Inc.’s EPS estimate?
Sensus Healthcare, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Sensus Healthcare, Inc. have?
Sensus Healthcare, Inc. has 16,462,059 shares outstanding.
What happened to Sensus Healthcare, Inc.’s price movement after its last earnings report?
Sensus Healthcare, Inc. reported an EPS of -$0.16 in its last earnings report, missing expectations of -$0.125. Following the earnings report the stock price went down -25.061%.
Which hedge fund is a major shareholder of Sensus Healthcare, Inc.?
Currently, no hedge funds are holding shares in SRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sensus Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (60.98% Upside)
$5.67 (60.98% Upside)
Blogger Sentiment
Bullish
SRTS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 40.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.68%
12-Months-Change
Fundamentals
Return on Equity
-15.79%
Trailing 12-Months
Asset Growth
-14.39%
Trailing 12-Months
Company Description
Sensus Healthcare, Inc.
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.
SRTS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but strategically constructive picture: strong operational catalysts (dedicated CPT codes, ~300% reimbursement increase, SensusLink launch, shipment activity, 8% treatment volume growth, solid cash position) that support a transition toward recurring revenue and broader adoption, contrasted with a sharp year-over-year revenue decline (~59%), significant margin compression (gross margin down to 29.2% from 52.2%), a larger adjusted EBITDA loss, and near-term revenue recognition/mix headwinds. Management is optimistic about sequential improvement (Q2 > Q1 and H2 > H1) and achieving full‑year profitability, but near-term financial performance remains challenged during the transition.View all SRTS earnings summariesSRTS Stock 12 Month Forecast
Average Price Target
$5.67
▲(60.98% Upside)
Technical Analysis
Ownership Overview
9.15% Insiders
8.81% Mutual Funds
10.42% Other Institutional Investors
66.63% Public Companies and
Individual Investors










